- PSI Oxus- ColoAD 1003-Phase 1 multicentre, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors.
Epithelial Tumors
April 12, 2019
April 12, 2019